<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625897</url>
  </required_header>
  <id_info>
    <org_study_id>A002-A7</org_study_id>
    <nct_id>NCT01625897</nct_id>
  </id_info>
  <brief_title>A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia</brief_title>
  <official_title>A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety, tolerability, and efficacy
      of MP-214 in patients with chronic phase or elderly schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>60 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>MP-214 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MP-214 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-214 low dose</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214</description>
    <arm_group_label>MP-214 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-214 high dose</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for four weeks, then flexible dose of MP-214</description>
    <arm_group_label>MP-214 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for two weeks, then flexible dose of risperidone</description>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from the patient before the initiation of any
             study-specific procedures

          -  Patients diagnosed with schizophrenia according to the diagnostic criteria of the
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
             (DSM-IV-TR) criteria for schizophrenia

          -  Patients who meet at least one of the following:

               -  current diagnosis of schizophrenia of chronic phase

               -  between 65 and 74 years of age

          -  Patients with normal physical examination, laboratory, vital signs, and/or
             electrocardiogram (ECG)

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform
             disorder, other psychotic disorders other than schizophrenia, or bipolar I or II
             disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Aizuwakamatsu</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>April 17, 2015</last_update_submitted>
  <last_update_submitted_qc>April 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Mental Disorder</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <keyword>Dopamine Agents</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

